跳至主要内容
临床试验/NCT06497777
NCT06497777招募中不适用

The Application of DNA Nanomachines for Detecting microRNA in Blood for the Diagnosis of Pancreatic Cancer.

National Taiwan University Hospital1 个研究点 分布在 1 个国家目标入组 30 人开始时间: 2024年7月6日最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
入组人数
30
试验地点
1
主要终点
Ratio of the target microRNA in patients with and without pancreatic adenocarcinoma.

研究概览

简要总结

Previous research has shown that microRNAs in the blood can serve as biomarkers for early pancreatic cancer, with potential applications including detection, differential diagnosis, and prognosis prediction of pancreatic cancer. The current primary method for detecting microRNAs is RT-qPCR, but this process requires repeated temperature cycling, which demands high precision from the equipment. As an alternative, isothermal nucleic acid amplification technology does not require expensive temperature control instruments. Our research team has developed various isothermal nucleic acid amplification strategies for microRNA sensing platforms, applied to biological sample detection. This study combines the circular strand displacement amplification strategy with DNA nanomachines to develop a fluorescence sensing platform that performs dual signal amplification at a constant temperature. It is designed to detect pancreatic cancer-related microRNAs, exploring its role and potential applications in the diagnosis of pancreatic cancer patients.

研究设计

研究类型
Observational
观察模型
Case Control
时间视角
Prospective

入排标准

年龄范围
20 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Pancreatic ductal adenocarcinoma
  • Proven by pathology
  • Patients who have not received anti-cancer therapies

排除标准

  • Less than 20 years old
  • Unable to provide inform and consent
  • Patients who have active malignancy other than pancreatic adenocarcinoma
  • Patients who have had pancreatic cancer whose anti-cancer therapies are completed or undergoing
  • Life expectancy less than 3 months

结局指标

主要结局

Ratio of the target microRNA in patients with and without pancreatic adenocarcinoma.

时间窗: 24 hours

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验